Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer

EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies

(2022) Ivana Samaržija et al.   Cancers

EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes

(2022) Jinqiang Zhang et al.   AMERICAN JOURNAL OF PATHOLOGY

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors

(2022) Haruka Shinohara et al.   Molecular Therapy-Oncolytics

Tazemetostat: First Approval

(2020) Sheridan M. Hoy   DRUGS

EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma

(2020) Jessamy Tiffen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review

(2020) Dino Bekric et al.   Journal of Clinical Medicine

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

(2020) Franck Morschhauser et al.   LANCET ONCOLOGY

Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives

(2020) Noemi Simeone et al.   Future Oncology

Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer

(2020) Xiao Tan et al.   Cell Death & Disease

EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy

(2019) Julian Puppe et al.   CLINICAL CANCER RESEARCH

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

(2019) Florian Moik et al.   Scientific Reports

Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers

(2019) Liye Zhou et al.   CLINICAL CANCER RESEARCH

PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation

(2019) Evan Healy et al.   MOLECULAR CELL

Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma

(2019) Ni Wang et al.   Cell Death & Disease

EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway

(2019) Hanwen Zhang et al.   ONCOGENE

Miniaturization of the Clonogenic Assay Using Confluence Measurement

(2018) Christian Mayr et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting EZH2 with tazemetostat

(2018) Shinichi Makita et al.   LANCET ONCOLOGY

Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway

(2018) Wei Zhao et al.   LIFE SCIENCES

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity

(2017) Laurel T. Bate-Eya et al.   EUROPEAN JOURNAL OF CANCER

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

(2017) Dorothy Brach et al.   MOLECULAR CANCER THERAPEUTICS

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro

(2016) Jacson K. Shen et al.   Scientific Reports

The role of polycomb repressive complexes in biliary tract cancer

(2014) Christian Mayr et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3

(2014) Bo Tang et al.   MEDICAL ONCOLOGY

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

(2014) S. K. Knutson et al.   MOLECULAR CANCER THERAPEUTICS

EZH2 Regulates the Expression of p16 in the Nasopharyngeal Cancer Cells

(2013) Jing Zhong et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Current status of chemotherapy for the treatment of advanced biliary tract cancer

(2013) Takashi Sasaki et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

(2012) W. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma

(2011) Dong-Cai Liu et al.   PATHOLOGY RESEARCH AND PRACTICE

Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo

(2010) Sha Hu et al.   CANCER BIOLOGY & THERAPY

Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer

(2010) Martin Sauvageau et al.   Cell Stem Cell

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Management of Gallbladder Carcinoma

(2010) A. X. Zhu et al.   ONCOLOGIST

Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma

(2009) Junpei Yamaguchi et al.   CANCER SCIENCE

Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin

(2009) Junpei Yamaguchi et al.   LABORATORY INVESTIGATION